FGFR1 amplification or overexpression is prevalent in various tumor types, with the highest rates observed in lung squamous cell carcinoma, breast cancer, bladder cancer, head and neck squamous cell carcinoma, and endometrial cancer. Here, FGFR1 is linked to neoplasm.